Johnson & Johnson (JNJ)
153.58
+1.15 (0.75%)
NYSE · Last Trade: May 30th, 12:15 AM EDT
Detailed Quote
Previous Close | 152.43 |
---|---|
Open | 151.75 |
Bid | 152.00 |
Ask | 153.95 |
Day's Range | 151.56 - 154.04 |
52 Week Range | 140.68 - 169.99 |
Volume | 6,811,016 |
Market Cap | 403.71B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 4.960 (3.23%) |
1 Month Average Volume | 7,855,327 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases

Via The Motley Fool · May 29, 2025

Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.
Via Investor's Business Daily · May 29, 2025

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.
By Johnson & Johnson · Via Business Wire · May 28, 2025
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Via Benzinga · May 27, 2025
Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.
Via Benzinga · May 27, 2025
Via The Motley Fool · May 27, 2025
Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors.
Via Chartmill · May 26, 2025
Via The Motley Fool · May 25, 2025
Via The Motley Fool · May 24, 2025
A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals.
By Beasley Allen Law Firm · Via Business Wire · May 23, 2025
Via The Motley Fool · May 23, 2025
For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider
Via MarketBeat · May 22, 2025
Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · May 21, 2025
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again.
Via The Motley Fool · May 18, 2025
U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals.
Via Benzinga · May 16, 2025
Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed cancer after prolonged use of the company’s talc-based products.
By Nachawati Law Group · Via Business Wire · May 15, 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
Via Benzinga · May 15, 2025
Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · May 14, 2025